Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...
Researchers from Eli Lilly & Co. presented the discovery and preclinical characterization of a novel protein tyrosine kinase 7 (PTK7)-targeting antibody-drug conjugate (ADC), LY-4175408, being ...
The mixed results are a blow for bepranemab and for related antibodies that target a mid-region epitope on tau. But exploratory analyses of the results hint at a path forward for these candidates.
Therapeutic antibodies are an important alternative option, but resistance has developed owing to the emergence of viral variants. A new paper in Cell reports the development of an antibody with ...
ISLAMABAD: The Islamabad High Court (IHC) set aside the Medical and Dental College Admission Test (MDCAT) 2024 results and ordered to reconduct it, ARY News reported. In its order, the IHC ...
ISLAMABAD: Two benches of the Islamabad High Court (IHC) issued contrasting rulings on identical cases concerning access to imprisoned former prime minister Imran Khan. IHC Chief Justice Aamer ...
Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 465-8603, Japan Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural ...
Scientists have developed an innovative antibody platform aimed at tackling one of the greatest challenges in treating rapidly evolving viruses like SARS-CoV-2: their ability to mutate and evade ...
About clesrovimab (MK-1654) Clesrovimab (MK-1654) is an investigational, extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV. Clesrovimab is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback